Browse
Submit Data
Databases
API
Help

Dataset Information

7 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Phase 1 Combination Study of MM-151 With MM-121, MM-141, or Trametinib

ABSTRACT: This is a Phase 1 open-label, dose-escalation trial using "3+3" design, evaluating MM-151 co-administration with MM-121, MM-141, and trametinib at varying dose levels.

DISEASE(S): Squamous Cell Carcinoma Of Head And Neck,Squamous Cell Carcinoma Of The Head And Neck,Non-small Cell Lung Cancer,Colorectal Cancer,Cancer

PROVIDER: 2197256 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment

Project description:This study is a Phase 1 and pharmacologic open-labeled dose-escalation trial using a "3+3" design, evaluating MM-151 at varying dose levels and frequencies, and subsequently in combination with irinotecan.

| 2119391 | ecrin-mdr-crc

Evaluation of MM-151 + Nal-IRI + 5-FU + Leucovorin in RAS/RAF Wild-type Metastatic Colorectal Cancer

Project description:A phase 1b/2a study evaluating the combination of MM-151 + nal-IRI + 5-FU + Leucovorin in RAS/RAF wild-type Metastatic Colorectal Cancer.

| 2216131 | ecrin-mdr-crc

XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation

Project description:This is a first-in-human multi-center study which will be conducted in advanced malignant solid tumors patients. The solid tumor type is limited to melanoma, colorectal, non-small-cell lung, and thyroid cancer with positive BRAF V600 mutation. This study is divided into three stages: Phase Ia: a dose-escalation phase of XP-102; Phase Ib: a dose-escalation and sample size expansion phase of XP-102 plus trametinib; Phase IIa: an expansion phase of XP-102 plus trametinib.

| 2708993 | ecrin-mdr-crc

Proteomics analysis of cerebrospinal fluid (CSF) from multiple sclerosis patients

Project description:Innovative pro-regenerative treatment strategies for progressive multiple sclerosis (PMS), combining neuroprotection and immunomodulation, represents an unmet need. Neural precursor cells (NPCs) transplanted in animal models of multiple sclerosis promote neuroprotection and remyelination by releasing molecules sustaining trophic support and neural plasticity. We present the results of STEMS, a single dose escalation phase I clinical trial, evaluating the feasibility, safety, and tolerability of intrathecally transplanted human fetal NPCs (hfNPCs) in 12 PMS patients.

2022-11-18 | PXD034846 | Pride

Proteomics analysis of cerebrospinal fluid (CSF) from multiple sclerosis patients

2022-11-18 | PXD034840 | Pride

Cellulosimicrobium sp. MM strain:MM

Project description:Cellulosimicrobium sp. MM strain:MM Genome sequencing and assembly

| PRJNA255748 | ENA

Emticicia sp. MM strain:MM

Project description:Emticicia sp. MM strain:MM Genome sequencing and assembly

| PRJNA316534 | ENA

Differentially expressed genes in iKRAS cell treated with Trametinib, 2DG and Combo

Project description:To identify the differentially expressed gene in ikras cells treated with Trametinib, 2DG and Trametinib/2DG combination. Two ikras cells were used for transcriptomics analysis by RNAseq.

2021-06-07 | GSE176242 | GEO

Genome-wide screening reveals the key genes that are responsible for trametinib-induced apoptosis

Project description:To explore the geness that are responsible for trametinib-induced apoptosis, we performed Genome-scale CRISPR-Cas9 knockout screening in GSU with 0.015% DMSO or 15 nM trametinib for 14 days. We found that TP53 is critical for executing trametinib-induced apoptosis.

2023-06-19 | GSE152846 | GEO

Response and resistance of low grade ovarian cancer cells to trametinib

Project description:HOC-7 and MPSC1 are low grade serous ovarian cancer cell lines. These cells was treated with different doses of trametinib in an attempt to identify biomarkers that can be used to predict chemoresponse to this drug. We used microarrays to identify genes induced by trametinib.

2020-04-15 | GSE148648 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data